Doxorubicin triggers splenic contraction and irreversible dysregulation of COX and LOX that alters the inflammation-resolution program in the myocardium
- 1 November 2018
- journal article
- research article
- Published by American Physiological Society in American Journal of Physiology-Heart and Circulatory Physiology
- Vol. 315 (5) , H1091-H1100
Abstract
Doxorubicin (DOX) is a widely used drug for cancer treatment as a chemotherapeutic agent. However, the cellular and integrative mechanism of DOX-induced immunometabolism is unclear. Two-month-old male C57BL/6J mice were divided into high- and low-dose DOX-treated groups with a maintained saline control group. The first group was injected with a high dose of DOX (H-DOX; 15 mg·kg−1·wk−1), and the second group was injected with 7.5 mg·kg−1·wk−1 as a latent low dose of DOX (LL-DOX). H-DOX treatment led to complete mortality in 2 wk and 70% survival in the LL-DOX group compared with the saline control group. Therefore, an additional group of mice was injected with an acute high dose of DOX (AH-DOX) and euthanized at 24 h to compare with LL-DOX and saline control groups. The LL-DOX and AH-DOX groups showed obvious apoptosis and dysfunctional and structural changes in cardiac tissue. Splenic contraction was evident in AH-DOX- and LL-DOX-treated mice, indicating the systems-wide impact of DOX on integrative organs of the spleen, which is essential for cardiac homeostasis and repair. DOX dysregulated splenic-enriched immune-sensitive lipoxygenase and cyclooxygenase in the spleen and left ventricle compared with the saline control group. As a result, lipoxygenase-dependent D- and E-series resolvin precursors, such as 16HDoHE, 4HDoHE, and 12-HEPE, as well as cyclooxygenase-mediated PG species (PGD2, PGE2, and 6-keto-PG2α) were decreased in the left ventricle, suggestive of defective immunometabolism. Both AH-DOX and LL-DOX induced splenic contraction and expansion of red pulp with decreased CD169+ metallophilic macrophages. AH-DOX intoxicated macrophages in the spleen by depleting CD169+ cells in the acute setting and sustained the splenic macrophage loss in the chronic phase in the LL-DOX group. Thus, DOX triggers a vicious cycle of splenocardiac cachexia to facilitate defective immunometabolism and irreversible macrophage toxicity and thereby impaired the inflammation-resolution program. NEW & NOTEWORTHY Doxorubicin (DOX) triggered splenic mass loss and decreased CD169 with germinal center contraction in acute and chronic exposure. Cardiac toxicity of DOX is marked with dysregulation of immunometabolism and thereby impaired resolution of inflammation. DOX suppressed physiological levels of cytokines and chemokines with signs of splenocardiac cachexia.Keywords
Funding Information
- HHS | NIH | National Heart, Lung, and Blood Institute (NHBLI) (HL132989)
This publication has 40 references indexed in Scilit:
- Dietary inorganic nitrate alleviates doxorubicin cardiotoxicity: Mechanisms and implicationsNitric Oxide, 2012
- Cardioprotective activity of standardized extract ofFicus racemosastem bark against doxorubicin-induced toxicityPharmaceutical Biology, 2011
- Role of heat shock factor-1 activation in the doxorubicin-induced heart failure in miceAmerican Journal of Physiology-Heart and Circulatory Physiology, 2010
- Cyclooxygenases: structural and functional insightsJournal of Lipid Research, 2009
- Anthracycline associated cardiotoxicity in survivors of childhood cancerHeart, 2008
- Congestive heart failure in patients treated with doxorubicinCancer, 2003
- Doxorubicin-induced Apoptosis Is Associated with Increased Transcription of Endothelial Nitric-oxide SynthaseJournal of Biological Chemistry, 2001
- Doxorubicin-induced Apoptosis in Endothelial Cells and Cardiomyocytes Is Ameliorated by Nitrone Spin Traps and EbselenJournal of Biological Chemistry, 2000
- Doxorubicin-Induced CardiomyopathyNew England Journal of Medicine, 1998
- Endothelial Nitric Oxide Synthase-Dependent Superoxide Generation from AdriamycinBiochemistry, 1997